Dong-A St (170900) - Total Assets
Based on the latest financial reports, Dong-A St (170900) holds total assets worth ₩1.41 Trillion KRW (≈ $956.92 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check Dong-A St (170900) total reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Dong-A St - Total Assets Trend (2013–2025)
This chart illustrates how Dong-A St's total assets have evolved over time, based on quarterly financial data. Explore 170900 long-term investments to assets to see how much of total assets are deployed in long-term investments.
Dong-A St - Asset Composition Analysis
Current Asset Composition (December 2025)
Dong-A St's total assets of ₩1.41 Trillion consist of 43.8% current assets and 56.2% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 11.6% |
| Accounts Receivable | ₩128.39 Billion | 9.1% |
| Inventory | ₩162.48 Billion | 11.5% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩123.05 Billion | 8.7% |
| Goodwill | ₩22.00 Billion | 1.6% |
Asset Composition Trend (2013–2025)
This chart illustrates how Dong-A St's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see how much is Dong-A St worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Dong-A St's current assets represent 43.8% of total assets in 2025, an increase from 37.4% in 2013.
- Cash Position: Cash and equivalents constituted 11.6% of total assets in 2025, down from 14.2% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 9.0% of total assets, an increase from 1.0% in 2013.
- Asset Diversification: The largest asset category is inventory at 11.5% of total assets.
Dong-A St Competitors by Total Assets
Key competitors of Dong-A St based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI
|
Sweden | Skr81.26 Billion |
|
Aurobindo Pharma Limited
NSE:AUROPHARMA
|
India | Rs585.02 Billion |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
|
China | CN¥14.18 Billion |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858
|
China | CN¥19.57 Billion |
|
Tianjin Chase Sun Pharmaceutical Co Ltd
SHE:300026
|
China | CN¥10.37 Billion |
|
Zhejiang Hisoar Pharmaceutical Co Ltd
SHE:002099
|
China | CN¥7.28 Billion |
|
Xeris Pharmaceuticals Inc
NASDAQ:XERS
|
USA | $392.01 Million |
|
Procter & Gamble Health Limited
NSE:PGHL
|
India | Rs8.94 Billion |
Dong-A St - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.52 | 2.38 | 2.93 |
| Quick Ratio | 1.12 | 1.80 | 2.24 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ₩212.53 Billion | ₩340.23 Billion | ₩307.51 Billion |
Dong-A St - Advanced Valuation Insights
This section examines the relationship between Dong-A St's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.65 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 1.5% |
| Total Assets | ₩1.41 Trillion |
| Market Capitalization | $238.87 Million USD |
Valuation Analysis
Below Book Valuation: The market values Dong-A St's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Dong-A St's assets grew by 1.5% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Dong-A St (2013–2025)
The table below shows the annual total assets of Dong-A St from 2013 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | ₩1.41 Trillion ≈ $956.92 Million |
+1.46% |
| 2024-12-31 | ₩1.39 Trillion ≈ $943.16 Million |
+10.07% |
| 2023-12-31 | ₩1.26 Trillion ≈ $856.88 Million |
+9.22% |
| 2022-12-31 | ₩1.16 Trillion ≈ $784.57 Million |
+3.74% |
| 2021-12-31 | ₩1.12 Trillion ≈ $756.29 Million |
+13.80% |
| 2020-12-31 | ₩980.67 Billion ≈ $664.58 Million |
-2.79% |
| 2019-12-31 | ₩1.01 Trillion ≈ $683.63 Million |
+6.34% |
| 2018-12-31 | ₩948.67 Billion ≈ $642.90 Million |
+5.44% |
| 2017-12-31 | ₩899.72 Billion ≈ $609.73 Million |
-15.65% |
| 2016-12-31 | ₩1.07 Trillion ≈ $722.83 Million |
+0.29% |
| 2015-12-31 | ₩1.06 Trillion ≈ $720.75 Million |
-1.69% |
| 2014-12-31 | ₩1.08 Trillion ≈ $733.16 Million |
+16.11% |
| 2013-12-31 | ₩931.72 Billion ≈ $631.41 Million |
-- |
About Dong-A St
Dong-A ST Co., Ltd. develops, manufactures, and markets pharmaceutical products in South Korea and internationally. It offers various ethical drugs, including Clofazimine cap. for lepromatous leprosy; Closerin Cap for active pulmonary and extra-pulmonary tuberculosis; Eporon inj./PFS for anemia associated with chronic renal failure; Gemcit inj. to treat non-small cell lung, pancreatic, breast, bl… Read more